Benjamin Derman, MD, is an Assistant Professor of Medicine, specializing in hematology and oncology at the University of Chicago Medical Center, The University of Chicago, Chicago, IL. Dr Derman completed his medical degree in 2013 at the Northwestern University Feinberg School of Medicine, Chicago, IL. Following this, he undertook his residency and chief residency programs in internal medicine in 2016 and 2017 respectively, at the Rush University Medical Center, Chicago, IL. Then, he completed his fellowship in hematology/oncology in 2020 at The University of Chicago.
Dr Derman also holds memberships to the following societies: the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology and the American Society of Hematology.
Speaking on targeted therapies and CAR T-cell therapies for multiple myeloma
Along with his clinical practice, Dr Derman remains committed to research. His research for the possible cure of multiple myeloma includes using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making. Dr Derman’s research in improving outcomes and quality of life for his patients involves evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients.